Abstract
Inhibition of catechol catechol-O-methyltransferase (COMT) in the brains of subjects treated with L-DOPA (L-3,4-dihydroxylphenylalanine) and an aromatic amino acid decarboxylase (AADC) inhibitor is suggested to cause an increase of L-DOPA, which might lead to oxidative damage through enhanced formation of free radicals. To investigate this hypothesis, the acute effects of two doses of the systemically administered COMT inhibitors entacapone (peripheral) and tolcapone (peripheral and central) on the extracellular formation of hydroxyl radicals in vivo following treatment with L-DOPA and the AADC inhibitor carbidopa were examined. The formation of extracellular hydroxyl radicals were determined by the measurement of 2,3-dihydroxybenzoic acid (2,3-DHBA), a reaction product of hydroxyl radicals with sodium salicylate, using microdialysis in the striatum of anesthetised rats. The COMT inhibitors were administered together with 50 mg/kg i.p. carbidopa as 5% gum arabic suspensions intraperitoneally (i.p.) at doses of 0, 1.0, and 10 mg/kg body weight to a total of 36 male HAN-Wistars rats. L-DOPA was injected i.p. 40 min after drugs of interest. Microdialysis samples were collected every 20 min for 400 min at a perfusion rate of 1 micr...Continue Reading
References
Aug 7, 1992·Brain Research·S Kaakkola, R J Wurtman
Jul 1, 1992·Journal of Neurochemistry·E AcquasG Di Chiara
Mar 1, 1992·British Journal of Pharmacology·P T MännistöR K Tuominen
Aug 1, 1991·Journal of Neurochemistry·E E BrownH C Fibiger
Aug 13, 1990·Brain Research·E D AbercrombieM J Zigmond
Feb 24, 1995·Neuroscience Letters·T KarhunenP Panula
Feb 6, 1995·European Journal of Pharmacology·A NapolitanoM Da Prada
Feb 3, 1995·Journal of Chromatography. B, Biomedical Applications·M PatthyI Sziráki
Sep 1, 1994·Neuroscience·A KastnerE C Hirsch
Sep 1, 1994·General Pharmacology·S KaakkolaP T Männistö
Jan 1, 1994·Pharmacology & Therapeutics·M E GötzM B Youdim
Jul 1, 1994·Journal of Neurochemistry·S R Wachtel, E D Abercrombie
Jan 1, 1993·Journal of Neurochemistry·S Kaakkola, R J Wurtman
Dec 1, 1995·Free Radical Biology & Medicine·J MontgomeryL Vachon
Jan 1, 1997·Journal of Neural Transmission·T BrannanM D Yahr
Apr 1, 1997·Acta Neurologica Scandinavica·V V MyllyläE H Heinonen
Apr 16, 1998·European Journal of Pharmacology·E NissinenI B Lindén
Oct 27, 1998·Lancet·W KuhnT Müller
Dec 19, 1998·Neuroscience Letters·M GerlachK H Sontag
Sep 24, 1999·Movement Disorders : Official Journal of the Movement Disorder Society·J L MontastrucJ M Senard
Feb 29, 2000·Journal of Neurochemistry·D M CampP A LeWitt
Nov 10, 2000·Journal of Neural Transmission·W StaffenG Ladurner
Citations
Sep 21, 2004·Naunyn-Schmiedeberg's Archives of Pharmacology·Markus M ForsbergPekka T Männistö
Apr 15, 2004·Neurochemistry International·Alvaro Hermida-AmeijeirasRamón Soto-Otero
Feb 8, 2003·Parkinsonism & Related Disorders·Alessandro NapolitanoUbaldo Bonuccelli
Dec 24, 2009·Cardiovascular Psychiatry and Neurology·Thomas Müller
Apr 17, 2007·Journal of Neurosurgery·Amy K WagnerC Edward Dixon
Oct 27, 2004·Naunyn-Schmiedeberg's Archives of Pharmacology·Manfred GerlachPeter Riederer
Oct 22, 2002·Expert Opinion on Pharmacotherapy·Thomas Müller
May 12, 2009·Biochemical Pharmacology·Jofre Tenorio-LarangaJ Arturo García-Horsman
Oct 24, 2013·Neuropharmacology·M J BonifácioP Soares-da-Silva
Jun 27, 2020·Fortschritte der Neurologie-Psychiatrie·Dirk WoitallaUllrich Wüllner